Fierce Pharma

AUGUST 17, 2023

Merck cancer superstar Keytruda is projected to be the world’s top selling drug by a huge margin in 2028, according to a report by Evaluate. On its list of top 10 drugs by sales in 2028, Keytruda is expected to top the $30 billion mark, with no other therapy predicted to reach $20 billion in sales.

98

98

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

145

145

Pharmafile

MARCH 30, 2023

After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. The drug is still awaiting approval in the EU and Japan, with these approvals potentially making it the top-selling Alzheimer’s drug.

FDA 83

FDA 83

Fierce Pharma

JANUARY 8, 2024

investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” | While some Merck & Co. While some Merck & Co.

Vaccines 132

Vaccines 132

Fierce Pharma

APRIL 23, 2024

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.

132

132

Fierce Pharma

OCTOBER 31, 2023

As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff. |

124

124

Drug Topics

JANUARY 19, 2024

According to IQVIA's most recent Global Use of Medicine report, losses for originator products are projected to rise by over $80 billion over the next 5 years due to market introductions of new biosimilar and generic drugs.

98

98

Drug Store News

JANUARY 16, 2024

Overall, global use and spending on medicines is exceeding pre-pandemic growth rates and is expected to continue significantly above these trends through 2028.

52

52

STAT

AUGUST 13, 2024

In a press release, the company said that the cuts would help it extend its cash reserves from the second half of 2026 into 2028. The Bay Area biotech brought in $32 million during the quarter but also reported a net loss of $1.6 Continue to STAT+ to read the full story…

143

143

BioPharm

OCTOBER 9, 2024

The annual survey predicts that four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which will control 45% of all CMO capacity in Asia.

52

52

Fierce Pharma

APRIL 20, 2023

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028 zbecker Thu, 04/20/2023 - 10:19

52

52

Pharmaceutical Technology

OCTOBER 25, 2024

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Vaccines 98

Vaccines 98

Fierce Pharma

SEPTEMBER 27, 2023

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S.

FDA 116

FDA 116

STAT

NOVEMBER 19, 2024

patent expires in 2028. For Merck, the new under-the-skin, or subcutaneous, formulation of Keytruda could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when the medicine’s U.S. It is the best-selling medicine in the world.

Immunization 133

Immunization 133

STAT

MAY 14, 2024

Last December, the agency determined the confirmatory trial was not acceptable and asked the company to run yet another trial, which must be completed by February 2028.

Dosage 139

Dosage FDA 139

STAT

MARCH 25, 2024

With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood. Now, Vertex may be on the move again. Continue to STAT+ to read the full story…

110

110

Drug Store News

APRIL 24, 2023

The Appeals Court affirmed the validity of the patent expiring in 2028.

96

96

STAT

JANUARY 8, 2024

That could come as soon as 2028. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunization 123

Immunization 123

STAT

SEPTEMBER 12, 2024

The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. Continue to STAT+ to read the full story…

Vaccines 131

Vaccines 131

STAT

JUNE 3, 2024

Kaiser, which is both a health insurance company and a network of providers, said it wants to add at least five to six more health systems by 2028. Geisinger’s 10 hospitals and 1,700 employed physicians are now officially part of the group, known as Risant Health. Those other organizations are still a mystery.

Hospitals 126

Hospitals Health Insurance Companies Insurance 126

Outsourcing Pharma

DECEMBER 3, 2024

Discover how a strategic acquisition in pharma packaging is set to drive growth as the market aims to double by 2028

Packaging 75

Packaging 75

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

98

98

Pharmaceutical Technology

DECEMBER 18, 2024

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

59

59

STAT

SEPTEMBER 28, 2023

The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians. Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives.

Hospitals 136

Hospitals 136

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Pharmacy Times

AUGUST 18, 2022

Study results show a compound annual growth rate of 5.2% billion in revenue in 2021.

Compounding 65

Compounding 65

Fierce Pharma

FEBRUARY 8, 2024

Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

75

75

STAT

OCTOBER 29, 2024

Beginning in 2028, Dana-Farber will end its long and nationally acclaimed adult oncology partnership with Brigham and Women’s Hospital. Instead, it will team up with Beth Israel Deaconess Medical Center to  open a new freestanding  300-bed, $1.68 billion cancer hospital in the Longwood Medical Area.

Hospitals 88

Hospitals 88

pharmaphorum

APRIL 20, 2021

billion by 2028. billion in sales in 2028. Analyst Philippa Salter of GlobalData recently predicted that Kesimpta’s convenience will make it a sought-after option for RMS patients, driving global sales to $3.3 While it requires a clinic visit, Ocrevus only has to be administered twice a year.

Hospitals 111

Hospitals Documentation 111

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

52

52

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

52

52

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

FDA 59

FDA 59

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

52

52

pharmaphorum

APRIL 29, 2022

Meanwhile, rapid diagnostics has been identified as the biggest factor in cancer survival rates in the NHS Long Term Plan, which lays out a target to increase the proportion of cancers diagnosed at stages 1 and 2 from half to three quarters by 2028.

Hospitals 145

Hospitals 145

STAT

JULY 29, 2024

Thomas Schinecker, chief executive of the pharmaceutical company, said its first obesity drugs would come to market “significantly faster than people are expecting,” potentially by 2028. The treatments, acquired in a $3.1 reduction in weight compared with a placebo after four weeks.

Pharmaceutical Companies 106

Pharmaceutical Companies Pharmaceutical Companies 106

STAT

JANUARY 25, 2023

The data is a setback for Merck, which has been working to expand use of Keytruda, which has powered its growth for years but will lose exclusivity in 2028. The drug was being tested in combination with androgen deprivation therapy and Xtandi in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

94

94

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52